NanoString Technologies, Inc. is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. The company was founded by Krassen Dimitrov, Amber Ratcliffe, and Dwayne Dunaway in 2003, and is based in Seattle, Washington. NanoString's "nCounter Analysis System" is based on a digital molecular barcoding technology invented by Dimitrov and Dunaway in Leroy Hood's lab at the Institute for Systems Biology , and became commercially available in 2008. NanoString received a CE-mark designation for selling the Prosigna™ Breast Cancer Prognostic Gene Signature Assay in Israel and EU in September 2012, and in September 2013, NanoString received FDA 510 clearance for Prosigna. Wikipedia.
NanoString Technologies | Date: 2013-05-22
The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles, including microarrays and quantitative polymerase chain reaction assays, as well as kits comprising reagents for practicing the methods of the invention.
NanoString Technologies | Date: 2014-05-13
The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. This prediction model can be used to accurately predict the intrinsic subtype of a subject diagnosed with or suspected of having breast cancer.
NanoString Technologies | Date: 2015-08-04
Body fluid identification by mRNA profiling may allow extraction of contextual activity level information from forensic samples. Accordingly, a prototype multiplex digital gene expression method for forensic body fluid/tissue identification is provided, based upon solution hybridization of color-coded (e.g., NanoString) probes. For example, a model for gene expression in a sample from a single body fluid is provided and extended to mixtures of body fluids. A calculation of maximum likelihood estimates of body fluid quantities in a sample is performed, and use of likelihood ratios to test for the presence of each body fluid in a sample is described. A process/algorithm is described and, unlike conventional algorithms for detecting tissues and cells, may allow for zero false-positive fluid identifications across a plurality of samples. Such a protocol may facilitate routine use of mRNA profiling in casework (e.g., forensic) laboratories that previously has not been as reliable.
NanoString Technologies | Date: 2013-03-07
The present invention relates to compositions and methods for detection and quantification of individual target molecules in biomolecular samples. In particular, the invention relates to coded, labeled probes that are capable of binding to and identifying target molecules based on the probes label codes. Methods, computers, and computer program products for identifying target-specific sequences for inclusion in the probes are also provided, as are methods of making and using such probes. The probes can be used in diagnostic, prognostic, quality control and screening applications.
British Columbia Cancer Agency Branch and NanoString Technologies | Date: 2013-06-28
The application describes methods for predicting overall survival in subjects with breast cancer. The application also describes for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including gemcitabine. The application further describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including gemcitabine and administering the therapy in subjects when it is found that gemcitabine is likely to be effective.